Commitments and Contingencies - Additional Information (Details)						1 Months Ended			3 Months Ended
	Jan. 14, 2022 USD ($)	Oct. 12, 2021 USD ($)	Mar. 19, 2021 USD ($)	Jan. 25, 2021 USD ($)	Jan. 21, 2021 USD ($)	May 31, 2021	Sep. 30, 2018 Patent	Aug. 31, 2016	Jun. 30, 2021 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Oct. 04, 2021 USD ($)
Commitments And Contingencies [Line Items]
Reimbursement payment			$ 14,000,000.0
Development payments			10,000,000.0
Other current liabilities										$ 742,323	$ 741,425
Other current assets										14,638	$ 20,188
Pending Litigation | The Securities Class Action
Commitments And Contingencies [Line Items]
Proposed settlement as a loss in accrued expenses										$ 8,400,000		$ 8,400,000
Other current liabilities												$ 900,000
Pending Litigation | Stockholders Derivative Action
Commitments And Contingencies [Line Items]
Payment of settlement amount					$ 500,000
Assistance Publique - Hopitaux de Paris ("AP-HP") | License Agreement
Commitments And Contingencies [Line Items]
Agreement entered date							2018-09
Number of patent applications | Patent							3
Assistance Publique - Hopitaux de Paris ("AP-HP") | Private Acer | License Agreement
Commitments And Contingencies [Line Items]
Agreement entered date								2016-08
Relief Therapeutics Holding AG | Collaboration Agreement
Commitments And Contingencies [Line Items]
Upfront non-refundable payment received				$ 1,000,000.0
Cash payment received				10,000,000.0
Reimbursement payment			14,000,000.0	14,000,000.0
Repayment of outstanding balance of prior loan and interest			4,000,000.0	$ 4,000,000.0
Development payments			$ 20,000,000.0
Net profit split ratio based on territory			60.00%	60.00%
Percentage of royalty revenue received				15.00%
Milestone payment to be received			$ 6,000,000.0	$ 6,000,000.0
Relief Therapeutics Holding AG | Collaboration Agreement | First Development Payment
Commitments And Contingencies [Line Items]
Reimbursement payment									$ 10,000,000.0
Relief Therapeutics Holding AG | Collaboration Agreement | Second Development Payment
Commitments And Contingencies [Line Items]
Potential proceeds from development payments subject to acceptance of new drug													$ 10,000,000.0
Relief Therapeutics Holding AG | Collaboration Agreement | Maximum
Commitments And Contingencies [Line Items]
Development payments			$ 20,000,000.0	$ 20,000,000.0
Relief Therapeutics Holding AG | Collaboration Agreement | Secured Loan
Commitments And Contingencies [Line Items]
Debt instrument, term				12 months
Debt instrument, principal amount				$ 4,000,000.0
Debt instrument, interest rate				6.00%
Relief Therapeutics Holding AG | Waiver and Agreement
Commitments And Contingencies [Line Items]
Second tranche of development payment, expiry date	Jan. 14, 2022
Relief Therapeutics Holding AG | Waiver and Agreement | Second Development Payment
Commitments And Contingencies [Line Items]
Proceeds from second tranche of development payments subject to new drug application	$ 5,000,000.0
Proceeds from first tranche of development payments subject to new drug application		$ 5,000,000.0
Emory University | License Agreement
Commitments And Contingencies [Line Items]
Agreement entered date						2021-05